CHMP Adopts Positive Opinion for BAVENCIO(R)(avelumab) Plus Ax...
DARMSTADT, Germany and NEW YORK, September 20, 2019 /PRNewswire-AsiaNet / -- Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib [1]- Decision by the Eu...
Authors: LATEST ASIANET NEWS RELEASES